$LRSV $CBDL $PURA Research Recap Emerging CBD P
Post# of 4849
(Total Views: 249)
Posted On: 06/09/2021 3:32:16 PM
$LRSV $CBDL $PURA Research Recap
Emerging CBD Provider Plays in High Growth Market
https://www.goldmanresearch.com/202103171313/...rkets.html
INVESTMENT HIGHLIGHTS
Through its two subsidiaries, Link Reservations, Inc. (OTC – LRSV) is poised to generate a meaningful share in some of the fastest growing wellness markets, namely hemp-based CBD-infused products for pets and humans, and functional mushrooms. The Company offers diverse products in niche, high growth markets and is one of the few CBD products firms to offer products in the US and Europe.
The projected 40% compound annual growth rate (CAGR) for the Pet CBD market over the next few years illustrates the strong appetite for the offerings. Plus, the unprecedented pet ownership during the pandemic, especially by millennials, fuels this opportunity .
CBDs are used to treat anxiety, inflammation, pain, and other conditions. LRSV plans to introduce new mushroom-infused products to treat stress and sleep disorders.
The convergence of key markets such as pet care, CBDs, functional mushrooms and potentially psychedelic mushrooms should foster considerable growth, success, and valuation premiums for LRSV. We project revenue to grow from approximately $1M in 2021 to approach $5M in 2022, with meaningful operating profit.
Our target price of $0.10 represents a premium to key LRSV peers. Given its competitive advantages, we believe that LRSV should trade at a premium to other CBD-infused product companies.
Emerging CBD Provider Plays in High Growth Market
https://www.goldmanresearch.com/202103171313/...rkets.html
INVESTMENT HIGHLIGHTS
Through its two subsidiaries, Link Reservations, Inc. (OTC – LRSV) is poised to generate a meaningful share in some of the fastest growing wellness markets, namely hemp-based CBD-infused products for pets and humans, and functional mushrooms. The Company offers diverse products in niche, high growth markets and is one of the few CBD products firms to offer products in the US and Europe.
The projected 40% compound annual growth rate (CAGR) for the Pet CBD market over the next few years illustrates the strong appetite for the offerings. Plus, the unprecedented pet ownership during the pandemic, especially by millennials, fuels this opportunity .
CBDs are used to treat anxiety, inflammation, pain, and other conditions. LRSV plans to introduce new mushroom-infused products to treat stress and sleep disorders.
The convergence of key markets such as pet care, CBDs, functional mushrooms and potentially psychedelic mushrooms should foster considerable growth, success, and valuation premiums for LRSV. We project revenue to grow from approximately $1M in 2021 to approach $5M in 2022, with meaningful operating profit.
Our target price of $0.10 represents a premium to key LRSV peers. Given its competitive advantages, we believe that LRSV should trade at a premium to other CBD-infused product companies.
(0)
(0)